Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

The US subsidiary of South Korea-based Celltrion today announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo) ...

Celltrion USA announced that Stoboclo (denosumab-bmwo) and Osenvelt (denosumab-bmwo), biosimilars referencing Prolia ...

Celltrion USA launches 2 denosumab biosimilars, Stoboclo and Osenvelt, enhancing treatment options for osteoporosis and ...

South Korean biopharmaceutical firm Celltrion said Tuesday that it had released its denosumab biosimilars, Stoboclo and ...

Stoboclo and Osenvelt, FDA-approved biosimilars of Prolia and Xgeva, are now available in the U.S. for variois cancers and ...

SEOUL, July 11 (Yonhap) -- South Korean stocks turned lower late Friday morning on losses in tech and defense shares. The ...

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building an ...

Teva and Celltrion’s attempt to muscle in on the multi-billion dollar US cancer and inflammatory disease drug market has hit a setback after the FDA rejected two key biosimilars because of ...

Seoul stocks reached a near four-year high despite Trump's tariff threats. The Kospi gained 0.6 percent, led by individual ...